Published in Cancer J on December 16, 2009
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother (2011) 1.04
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest (2015) 0.96
Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol (2011) 0.92
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol (2013) 0.90
Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine (2010) 0.89
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology (2013) 0.88
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med (2012) 0.84
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol (2015) 0.80
Synthetic biology approaches to engineer T cells. Curr Opin Immunol (2015) 0.78
New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci (2016) 0.77
T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron (2013) 0.77
Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells. J Immunol (2013) 0.76
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Mol Ther Oncolytics (2016) 0.75